SPHDFSanthera Pharmaceuticals Holdings Ltd.

About Santhera Pharmaceuticals Holdings Ltd. (SPHDF)

Santhera Pharmaceuticals Holdings Ltd. (SPHDF) is a Biotechnology company headquartered in Pratteln, Switzerland whose shares trade over-the-counter on the Pink tier.

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy.

SPHDF key facts

Ticker symbol

SPHDF

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Pratteln, Switzerland

Country of incorporation

CH

Estimated market cap

$1.00B (as of Apr 16, 2025)

Shares outstanding

60,927,311

Reporting standard

International Reporting: SIX Swiss Exchange

Audit status

Audited

Fiscal year end

12/31

Santhera Pharmaceuticals Holdings Ltd. leadership

• Barbara Heller — CFO
• Thomas Staffelbach — VP, Investor Rel.

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with S